HUP9903979A2 - Nitrogén(II)-oxid szintetáz inhibitorok alkalmazása II. típusú diabetes kezelésére - Google Patents

Nitrogén(II)-oxid szintetáz inhibitorok alkalmazása II. típusú diabetes kezelésére

Info

Publication number
HUP9903979A2
HUP9903979A2 HU9903979A HUP9903979A HUP9903979A2 HU P9903979 A2 HUP9903979 A2 HU P9903979A2 HU 9903979 A HU9903979 A HU 9903979A HU P9903979 A HUP9903979 A HU P9903979A HU P9903979 A2 HUP9903979 A2 HU P9903979A2
Authority
HU
Hungary
Prior art keywords
diabetes
inhibitors
treat
prevent type
type
Prior art date
Application number
HU9903979A
Other languages
English (en)
Inventor
Valerie Piercy
Nicholas Charles Turner
Original Assignee
Smithkline Beecham Plc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc. filed Critical Smithkline Beecham Plc.
Publication of HUP9903979A2 publication Critical patent/HUP9903979A2/hu
Publication of HUP9903979A3 publication Critical patent/HUP9903979A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

A találmány II. típűsú diabetes kezelésére és/vagy megelőzéséreszőlgáló eljárásra vőnatkőzik, amelynek sőrán egy embernek vagynemhűmán emlősnek egy NO-szintetáz inhibitőrnak, példáűl aminő-gűanidinnek vagy gyógyászatilag elfőgadható származékának hatásős,nemtőxikűs, gyógyászatilag elfőgadható mennyiségét adják be. Az egyikelőnyös találmány szerinti megőldás II. típűsú diabetes prőfilaktikűskezelési eljárására, különösen a hyperinsűlinaemiától ahyperglykaemiáig terjedő prőgresszió késleltetésére vagymegakadályőzására vőnatkőzik. ŕ
HU9903979A 1995-12-22 1996-12-18 Use of nitric oxidesynthase inhibitors to treat or prevent type ii diabetes HUP9903979A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9526331.5A GB9526331D0 (en) 1995-12-22 1995-12-22 Novel method
PCT/EP1996/005871 WO1997023204A1 (en) 1995-12-22 1996-12-18 Nitric oxide (no) synthase inhibitor to treat or prevent type ii diabetes

Publications (2)

Publication Number Publication Date
HUP9903979A2 true HUP9903979A2 (hu) 2000-03-28
HUP9903979A3 HUP9903979A3 (en) 2000-05-29

Family

ID=10785930

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903979A HUP9903979A3 (en) 1995-12-22 1996-12-18 Use of nitric oxidesynthase inhibitors to treat or prevent type ii diabetes

Country Status (20)

Country Link
EP (1) EP0868175B1 (hu)
JP (1) JP2000502668A (hu)
KR (1) KR19990076595A (hu)
CN (1) CN1209057A (hu)
AT (1) ATE232724T1 (hu)
AU (1) AU1379497A (hu)
BR (1) BR9612245A (hu)
CA (1) CA2240396A1 (hu)
CZ (1) CZ198698A3 (hu)
DE (1) DE69626307T2 (hu)
ES (1) ES2193285T3 (hu)
GB (1) GB9526331D0 (hu)
HU (1) HUP9903979A3 (hu)
IL (1) IL124870A0 (hu)
MX (1) MX9805098A (hu)
NO (1) NO982854L (hu)
NZ (1) NZ325307A (hu)
PL (1) PL327472A1 (hu)
TR (1) TR199801133T2 (hu)
WO (1) WO1997023204A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044598A2 (en) * 1998-03-03 1999-09-10 Board Of Regents, The University Of Texas System Methods for inhibiting βcell apoptosis
CN1660428B (zh) * 2005-01-10 2011-09-07 王振军 一氧化氮合酶（nos）抑制剂用于治疗痔的新用途
ES2386831B1 (es) * 2011-02-04 2013-07-08 Servicio Andaluz De Salud Uso de inhibidores de la actividad de las NO sintasas (NOS) y sus composiciones, en la elaboración de un medicamento para el tratamiento y la prevención de la prediabetes y la diabetes mellitus tipo 1 (DM1)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT793646E (pt) * 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente

Also Published As

Publication number Publication date
ES2193285T3 (es) 2003-11-01
ATE232724T1 (de) 2003-03-15
NO982854D0 (no) 1998-06-19
NZ325307A (en) 1999-11-29
CA2240396A1 (en) 1997-07-03
PL327472A1 (en) 1998-12-07
KR19990076595A (ko) 1999-10-15
CN1209057A (zh) 1999-02-24
JP2000502668A (ja) 2000-03-07
NO982854L (no) 1998-06-19
CZ198698A3 (cs) 1999-06-16
TR199801133T2 (xx) 1998-09-21
MX9805098A (es) 1998-10-31
GB9526331D0 (en) 1996-02-21
WO1997023204A1 (en) 1997-07-03
HUP9903979A3 (en) 2000-05-29
DE69626307T2 (de) 2003-10-16
IL124870A0 (en) 1999-01-26
EP0868175B1 (en) 2003-02-19
EP0868175A1 (en) 1998-10-07
BR9612245A (pt) 1999-07-13
DE69626307D1 (de) 2003-03-27
AU1379497A (en) 1997-07-17

Similar Documents

Publication Publication Date Title
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
FI973492A (fi) NO-syntaasin estäjät
FR2740339B1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
HUP0104747A2 (hu) Ciklooxigenáz-2-gátlót és mátrix metalloproteináz-gátlót alkalmazó kombinált terápia daganatos betegségek (neoplasia) kezelésénél
IS5265A (is) Sertralín sölt og viðhalds-losandi skammtaform afsertralíni
ATE212546T1 (de) Behandlung von neurodegenerativen zuständen mittels nimesulide
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
NO953370D0 (no) Anvendelse av riluzol ved behandling av neuro-AIDS
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
HUP9903979A2 (hu) Nitrogén(II)-oxid szintetáz inhibitorok alkalmazása II. típusú diabetes kezelésére
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
BR0212989A (pt) Métodos para tratamento neuroprotetor usando inibidores de inos seletivos
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
HUP9903978A2 (hu) Proteinek glikozilezését inhibitáló vegyületek alkalmazása II. típusú diabetes kezelésére
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
KR940003550A (ko) 노인성 치매 예방 및 치료방법
HUP9904189A2 (hu) Eténtartalmú oldatok fertőzések elleni terápiás és profilaktikus alkalmazásra
DK1299102T3 (da) Anvendelse af riluzol eller salte deraf til forebyggelse og behandling af adrenoleukodystrofi
RU93051046A (ru) Способ борьбы с аскосферозом и гнильцовыми болезнями пчел
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.
KR960033467A (ko) 뮤신분비 억제제